2011 - ISBTS 2011 Symposium

This page contains exclusive content for the member of the following sections: TTS, ITA

Oral Communications 10: Immune & Infectious Monitoring

11.225 - Successful isolated intestinal transplantation in sensitized recipients with the use of virtual cross matching

Presenter: Jason, Hawksworth, Washington DC, United States
Authors: Jason Hawksworth1, Cal Matsumoto1, Raffaele Girlanda1, Juan Francisco Guerra1, Kimberly Christensen1, Chelsea Valdiconza1, Sandra Rosen-Bronson1, Stuart Kaufman1, Cheryl Little1, Kirti Shetty1, Jaqueline Laurin1, Rohit Satoskar1, Thomas Fishbein1

Successful isolated intestinal transplantation in sensitized recipients with the use of virtual cross matching

Jason Hawksworth, Cal Matsumoto, Raffaele Girlanda, Juan Francisco Guerra, Kimberly Christensen, Chelsea Valdiconza, Sandra Rosen-Bronson, Stuart Kaufman, Cheryl Little, Kirti Shetty, Jaqueline Laurin, Rohit Satoskar, Thomas Fishbein

Transplant Institute, Georgetown University Hospital, Washington, DC, United States

Given the high incidence of acute cellular rejection (ACR) following isolated intestinal transplantation (ITx), significant recipient sensitization is considered prohibitive by many centers. Virtual cross matching (VXM) may optimize organ allocation and minimize immunologic risk in sensitized recipients, enabling successful ITx transplantation.

Methods: Retrospective analysis of all isolated ITx performed in at our institution from 2003 to 2010. Allograft allocation in sensitized recipients was based on the results of a VXM in which the donor specific antibody (DSA) was evaluated. HLA antibody testing was done using a Luminex-based single-antigen assay.  All potential donors were screened against recipient DSA titers. DSA titers greater than 1:16 were considered prohibitive for isolated ITx. Standard immunosuppression (IS) consisted of IL2 blockade induction with maintenance IS of tacrolimus, sirolimus, and prednisone. Sensitized recipients received thymoglobulin induction and IVIG followed by standard maintenance IS. Intestinal biopsies were obtained on protocol. Standard grading was used for histological diagnosis of ACR.

Results: 65 isolated ITx transplants were performed in 63 patients (18 pediatric and 45 adult) with a mean follow up of 37.5 months. There were 21 sensitized recipients (5 pediatric and 16 adult) with a mean PRA of 52 ±34; 5 recipients were highly sensitized with PRA >80%. Donor and recipient clinical characteristics were well matched between the sensitized and non-sensitized patients. ITx outcomes, including TPN days, 1 year freedom from rejection (FFR), 1 year survival, and incidence of PTLD were not significantly different in sensitized compared to non-sensitized patients.

Conclusions: Utilizing a VXM strategy to optimize organ allocation and immunosuppression protocols, highly sensitized adult and pediatric patients can successfully undergo isolated intestinal transplantation with comparable short term outcomes to non-sensitized recipients.  Longer follow up is necessary to determine the late immunologic sequela of sensitization in isolated ITx.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory
This email address is being protected from spambots. You need JavaScript enabled to view it.


The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7